Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis

Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis - Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013712

Enrollment

Registered

2014-04-14

Start date

2011-12-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

GMA treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with steroid-refractory UC or steroid-dependent UC were recruited in this study and were scheduled to undergo GMA.

Exclusion criteria

Exclusion criteria: severe infectious disease number of granulocyte <=2000/mm3

Design outcomes

Primary

Measure	Time frame
Comparison of fecal lactoferrin concentrations between the GMA-responder and -nonresponder groups	—

Countries

Japan

Contacts

Public ContactFuminao Takeshima

Nagasaki University Hospital Gastroenterology and Hepatology

ftake@nagasaki-u.ac.jp095-819-7481

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026